Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PINNACLE: 89Zr-avelumab PET in NSCLC
NCT03514719Phase 1Completed
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2018
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zirconium-89 avelumab in non-small cell lung cancer (NSCLC), sponsored by Radboud University Medical Center. Primary endpoint: Tumor uptake of 89Zr-Avelumab at 1 year. Started Oct 2018; status: completed.
02
Drugs
zirconium-89 avelumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03514719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03514719.